Thyroid hormone receptor mutations and disease: insights from knock-in mouse models

References

• Oppenheimer JH. Thyroid hormone action at the nuclear level. Ann. Intern. Med.102(3), 374–384 (1985).
   PubMed Web of Science ®Google Scholar
• Samuels HH, Forman BM, Horowitz ZD, Ye ZS. Regulation of gene expression by thyroid hormone. J. Clin. Invest.81(4), 957–967 (1988).
   PubMed Web of Science ®Google Scholar
• Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. The c-erb A gene encodes a thyroid hormone receptor. Nature324(6098), 641–646 (1986).
   PubMed Web of Science ®Google Scholar
• Sap J, Munoz A, Damm K et al. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature324(6098), 635–640 (1986).
   PubMed Web of Science ®Google Scholar
• Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol. Cell. Endocrinol.213(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Cheng SY. Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev. Endocr. Metab. Disord1(1–2), 9–18 (2000).
   PubMedGoogle Scholar
• Cheng SY. Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol. Metab.16(4), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• O’Shea PJ, Harvey CB, Suzuki H et al. A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol. Endocrinol.17, 1410–1424 (2003).
   PubMedGoogle Scholar
• Wondisford FE. Thyroid hormone action: insight from transgenic mouse models. J. Investig. Med.51, 215–220 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang XY, Kaneshige M, Kamiya Y, Kaneshige K, McPhie P, Cheng SY. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant β receptor. Mol. Endocrinol.16(9), 2077–2092 (2002).
   PubMedGoogle Scholar
• Williams GR. Cloning and characterization of two novel thyroid hormone receptor β isoforms. Mol. Cell. Biol.20(22), 8329–8342 (2000).
   PubMed Web of Science ®Google Scholar
• Forrest D, Hallbook F, Persson H, Vennstrom B. Distinct functions for thyroid hormone receptors α and β in brain development indicated by differential expression of receptor genes. EMBO J.10(2), 269–275 (1991).
   PubMed Web of Science ®Google Scholar
• Bradley DJ, Towle HC, Young WS III. Spatial and temporal expression of α- and β-thyroid hormone receptor mRNAs, including the β 2-subtype, in the developing mammalian nervous system. J. Neurosci.12(6), 2288–2302 (1992).
   PubMed Web of Science ®Google Scholar
• Iskaros J, Pickar M, Evans I, Sinha A, Hardiman P, Ekins R. Thyroid hormone receptor gene expression in first trimester human fetal brain. J. Clin. Endocrinol. Metab.85(7), 2620–2623 (2000).
   PubMed Web of Science ®Google Scholar
• Horlein AJ, Naar AM, Heinzel T et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature377(6548), 397–404 (1995).
   PubMed Web of Science ®Google Scholar
• Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature377(6548), 454–457 (1995).
   PubMed Web of Science ®Google Scholar
• Tsai CC, Fondell JD. Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam. Horm.68, 93–122 (2004).
   PubMed Web of Science ®Google Scholar
• Moore JM, Guy RK. Coregulator interactions with the thyroid hormone receptor. Mol. Cell. Proteomics4(4), 475–482 (2005).
   PubMed Web of Science ®Google Scholar
• Yen PM, Ando S, Feng X, Liu Y, Maruvada P, Xia X. Thyroid hormone action at the cellular, genomic and target gene levels. Mol. Cell. Endocrinol.246(1–2), 121–127 (2006).
   PubMed Web of Science ®Google Scholar
• Weiss R, Refetoff S. Resistance to thyroid hormone. Rev. Endocr. Metab. Disord.1(1–2), 97–108 (2000).
   PubMedGoogle Scholar
• Yen PM. Molecular basis of resistance to thyroid hormone. Trends Endocrinol. Metab.14(7), 327–333 (2003).
   PubMed Web of Science ®Google Scholar
• Kaneshige M, Kaneshige K, Zhu X et al. Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl Acad. Sci. USA97(24), 13209–13214 (2000).
   PubMed Web of Science ®Google Scholar
• Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J. Clin. Endocrinol. Metab.27(2), 279–294 (1967).
   PubMed Web of Science ®Google Scholar
• Usala SJ, Bale AE, Gesundheit N et al. Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA β gene. Mol. Endocrinol.2(12), 1217–1220 (1988).
   PubMedGoogle Scholar
• Sakurai A, Takeda K, Ain K et al. Generalized resistance to thyroid hormone associated with a mutation in the ligand-binding domain of the human thyroid hormone receptor β. Proc. Natl Acad. Sci. USA86(22), 8977–8981 (1989).
   PubMed Web of Science ®Google Scholar
• Refetoff S. Resistance to thyroid hormone. In: Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text (9th Edition.). Braverman LE, Utiger RE (Eds). Lippincott, Williams and Wilkins, PA, USA 1109–1129 (2005).
   Google Scholar
• Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB. Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J. Clin. Endocrinol. Metab.73(5), 990–994 (1991).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Curty FH, Borges PP et al. An unliganded thyroid hormone receptor causes severe neurological dysfunction. Proc. Natl Acad. Sci. USA98(7), 3998–4003 (2001).
   PubMed Web of Science ®Google Scholar
• Siesser WB, Cheng SY, McDonald MP. Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRβPV knock-in mouse. Psychopharmacology (Berl.)181(4), 653–663 (2005).
   PubMed Web of Science ®Google Scholar
• Kamiya Y, Zhang XY, Ying H et al. Modulation by steroid receptor coactivator-1 of target-tissue responsiveness in resistance to thyroid hormone. Endocrinology144(9), 4144–4153 (2003).
   PubMed Web of Science ®Google Scholar
• Griffith AJ, Szymko YM, Kaneshige M et al. Knock-in mouse model for resistance to thyroid hormone (RTH): an RTH mutation in the thyroid hormone receptor β gene disrupts cochlear morphogenesis. J. Assoc. Res. Otolaryngol.3(3), 279–288 (2002).
   PubMedGoogle Scholar
• Ying H, Furuya F, Willingham MC, Xu J, O’Malley BW, Cheng SY. Dual functions of the steroid hormone receptor coactivator 3 in modulating resistance to thyroid hormone. Mol. Cell. Biol.25(17), 7687–7695 (2005).
   PubMed Web of Science ®Google Scholar
• Miller LD, McPhie P, Suzuki H, Kato Y, Liu ET, Cheng SY. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biol.5(5), R31 (2004).
   PubMedGoogle Scholar
• Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett.155(2), 145–152 (2000).
   PubMed Web of Science ®Google Scholar
• Silva JM, Dominguez G, Gonzalez-Sancho JM et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene21(27), 4307–4316 (2002).
   PubMed Web of Science ®Google Scholar
• Conde I, Paniagua R, Zamora J et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann. Oncol.17(1), 60–64 (2006).
   PubMedGoogle Scholar
• Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog.26(1), 53–61 (1999).
   PubMed Web of Science ®Google Scholar
• Horkko TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Makinen MJ. Thyroid hormone receptor β1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int. J. Cancer118(7), 1653–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Wallin G, Bronnegard M, Grimelius L, McGuire J, Torring O. Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid2(4), 307–313 (1992).
   PubMed Web of Science ®Google Scholar
• Bronnegard M, Torring O, Boos J, Sylven C, Marcus C, Wallin G. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab.79(2), 384–389 (1994).
   PubMed Web of Science ®Google Scholar
• Kamiya Y, Puzianowska-Kuznick M, McPhie P, Nauman J, Nauman J, Cheng SY. Expression of mutant thyroid hormone nuclear receptor is associated with human renal clear cell carcinoma. Carcinogenesis23(1), 25–33 (2002).
   PubMed Web of Science ®Google Scholar
• Puzianowska-Kuznick M, Krystyniak A, Madej A, Cheng SY, Nauman J. Contribution of functionally impaired thyroid hormone receptor mutants to the tumorigenesis of thyroid papillary cancer. J. Clin. Endocrinol. Metab.87(3), 1120–1128 (2002).
   PubMed Web of Science ®Google Scholar
• Lin KH, Zhu XG, Shieh HY et al. Identification of naturally occurring dominant negative mutants of thyroid hormone α 1 and β 1 receptors in a human hepatocellular carcinoma cell line. Endocrinology137(10), 4073–4081 (1996).
   PubMed Web of Science ®Google Scholar
• Lin KH, Zhu XG, Hsu HC et al. Dominant negative activity of mutant thyroid hormone α1 receptors from patients with hepatocellular carcinoma. Endocrinology138(12), 5308–5315 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Willingham MC, Cheng SY. Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid12(11), 963–969 (2002).
   PubMed Web of Science ®Google Scholar
• Ying H, Suzuki H, Furumoto H et al. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis24(9), 1467–1479 (2003).
   PubMed Web of Science ®Google Scholar
• Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY. Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis. Cancer Res.63(17), 5274–5280 (2003).
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPAR γ. Nat. Med.4(9), 1046–1052, (1998).
   PubMed Web of Science ®Google Scholar
• Kubota T, Koshizuka K, Williamson EA et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res.58(15), 3344–3352 (1998).
   PubMed Web of Science ®Google Scholar
• Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome proliferator-activated receptor on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab.87(10), 4728–4735 (2002).
   PubMed Web of Science ®Google Scholar
• Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab.86(5), 2170–2177 (2001).
   PubMed Web of Science ®Google Scholar
• Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPAR γ 1 fusion oncogene in human thyroid carcinoma. Science289(5483), 1357–1360 (2000).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARγrearrangement in thyroid tumors: Rt-PCR and immunohistochemical analyses. Am. J. Surg. Pathol.26(8), 1016–1023 (2002).
   PubMed Web of Science ®Google Scholar
• Cheung L, Messina M, Gill A et al. Detection of the PAX8-PPAR γ fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab.88(1), 354–357 (2003).
   PubMed Web of Science ®Google Scholar
• Gustafson KS, LiVolsi VA, Furth EE, Pasha TL, Putt ME, Baloch ZW. Peroxisome proliferator-activated receptor γ expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies. Am. J. Clin. Pathol.120(2), 175–181 (2003).
   PubMed Web of Science ®Google Scholar
• Kato Y, Ying H, Zhao L et al. Peroxisome proliferator activated receptor-γ insufficiency promotes carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene25(19), 2736–2747 (2006).
   PubMed Web of Science ®Google Scholar
• Araki O, Ying H, Furuya F, Zhu X, Cheng SY. Thyroid hormone receptor β mutants: dominant negative regulators of peroxisome proliferator-activated receptor γ action. Proc. Natl Acad. Sci. USA102(45), 16251–16256 (2005).
   PubMed Web of Science ®Google Scholar
• Swanson EA, Gloss B, Belke DD, Kaneshige M, Cheng SY, Dillman WH. Cardiac expression and function of thyroid hormone receptor β and its PV mutant. Endocrinology144(11), 4820–4825 (2003).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Esaki T, Kaneshige M et al. Brain glucose utilization in mice with a targeted mutation in the thyroid hormone α or β receptor gene. Proc. Natl Acad. Sci. USA17(1), 9913–9918 (2001).
   Google Scholar
• Esaki T, Suzuki H, Cook M et al. Functional activation of cerebral metabolism in mice with mutated thyroid hormone nuclear receptors. Endocrinology144(9), 4117–4122 (2003).
   PubMed Web of Science ®Google Scholar
• Furumoto H, Ying H, Chandramouli GV et al. An unliganded thyroid hormone β receptor activates the cyclin D1/cyclin-dependent retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol. Cell. Biol.25(1), 124–135 (2005).
   PubMed Web of Science ®Google Scholar
• Wymann MP, Marone R. Phosphoinositude 3-kinase in disease: timing, location, and scaffolding. Curr. Opin. Cell Biol.17(2), 141–149 (2005).
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol.22(14), 2954–2963 (2004).
   PubMed Web of Science ®Google Scholar
• Eng C. PTEN: one gene, many syndromes. Hum. Mutat.22(3), 183–198 (2003).
   PubMed Web of Science ®Google Scholar
• Dahia PL, Marsh DJ, Zheng Z et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res.57, 4710–4713 (1997).
   PubMed Web of Science ®Google Scholar
• Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet.16(1), 64–67 (1997).
   PubMed Web of Science ®Google Scholar
• Ringel MD, Hayre N, Saito J et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res.61(16), 6105–6111 (2001).
   PubMed Web of Science ®Google Scholar
• Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr. J.50(1), 77–83 (2003).
   PubMed Web of Science ®Google Scholar
• Vasko V, Saji M, Hardy E et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J. Med. Genet.41(3), 161–170 (2004).
   PubMed Web of Science ®Google Scholar
• Kim CS, Vasko VV, Kato Y et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology146(10), 4456–4463 (2005).
   PubMed Web of Science ®Google Scholar
• Furuya F, Hanover J, Cheng S-y. Activation of the PI3K signaling by a mutant thyroid hormone β receptor. Proc. Natl Acad. Sci. USA103(6), 1780–1785 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu XG, Hanover JA, Hager GL, Cheng SY. Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor-green fluorescent protein chimera. J. Biol. Chem.273(42), 27058–27063 (1998).
   PubMed Web of Science ®Google Scholar
• Baumann CT, Maruvada P, Hager GL, Yen PM. Nuclear cytoplasmic shuttling by thyroid hormone receptors. Multiple protein interactions are required for nuclear retention. J. Biol. Chem.276(14), 11237–11245 (2001).
   PubMed Web of Science ®Google Scholar
• Asnaghi L, Bruno P, Priulla M, Nicolin A. mTOR: a protein kinase switching between life and death. Pharmacol. Res.50(6), 545–549 (2004).
   PubMed Web of Science ®Google Scholar
• Edwards LA, Shabbits JA, Bally M, Dedhar S. Integrin-linked kinase (ILK) in combination molecular targeting. Cancer Treat. Res.119, 59–75 (2004).
   PubMedGoogle Scholar
• Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol.3(3), 207–214 (2004).
   Web of Science ®Google Scholar
• Turpeenniemi-Hujanen, T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie87(3–4), 287–297 (2005).
   PubMed Web of Science ®Google Scholar
• Persad S, Dedhar S. The role of integrin-linked (ILK) in cancer progression. Cancer Metastasis Rev.22(4), 375–384 (2003).
   PubMed Web of Science ®Google Scholar
• Sadow P, Reutratkul S, Weiss RE, Refetoff S. Resistance to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes. Curr. Opin. Endocrinol. Diabetes7(5), 253–259 (2000).
   Google Scholar
• Refetoff S, Sadow PM, Reutrakul S et al. Resistance to thyroid hormone in the absence of mutations in the thyroid hormone receptor genes. In: Syndromes of Hormone Resistance on the Hypothalamic-Pituitary-Thyroid Axis. Beck-Peccoz P (Ed.). Kluwer Academic Publishers, MA, USA 89–107 (2004).
   Google Scholar
• Weiss RE, Xu J, Ning G et al. Mice deficient in the steroid receptor co-activator-1 (SRC-1) are resistant to thyroid hormone. EMBO J.18(7), 1900–1904 (1999).
   PubMed Web of Science ®Google Scholar
• Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am. J. Hum. Genet.74(1), 168–175 (2004). Erratum: 74(3), 598 (2004).
   PubMed Web of Science ®Google Scholar
• Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J. Biol. Chem.278(41), 40128–40135 (2003).
   PubMed Web of Science ®Google Scholar
• Jansen J, Friesema EC, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid15(8), 757–768 (2005).
   PubMed Web of Science ®Google Scholar
• Maranduba CM, Friesema EC, Kok F et al. Decreased cellular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter. J. Med. Genet.43(5), 457–460 (2006).
   PubMed Web of Science ®Google Scholar
• Kaneshige M, Suzuki H, Kaneshige K et al. A targeted dominant negative mutation of the thyroid hormone α1 receptor causes increased mortality, infertility and dwarfism in mice. Proc. Natl Acad. Sci. USA98(26), 15095–15100 (2001).
   PubMed Web of Science ®Google Scholar
• Esaki T, Suzuki H, Cook M et al. Cardiac glucose utilization in mice with mutated α- and β-thyroid hormone receptors. Am. J. Physiol. Endocrinol. Metab.287(6), E1149–E1153 (2004).
   Google Scholar
• Schaller RT Jr, Stevenson JK. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer19(8), 1063–1080 (1966).
   PubMed Web of Science ®Google Scholar
• Parma J, Duprez L, Van Sande J et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs genes as a cause of toxic thyroid adenomas. J. Clin. Endocrinol. Metab.82(8), 2695–2701 (1997).
   PubMed Web of Science ®Google Scholar
• Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J. Clin. Endocrinol. Metab.79(6), 1785–1789 (1994).
   PubMed Web of Science ®Google Scholar
• Russo D, Arturi F, Wicker R et al. Genetic alterations in thyroid hyperfunctioning adenomas. J. Clin. Endocrinol. Metab.80(4), 1347–1351 (1995).
   PubMed Web of Science ®Google Scholar
• Suarez HG, du Villard JA, Caillou B, Schlumberger M, Parmentier C, Monier R. Gsp mutations in human thyroid tumours. Oncogene6(4), 677–679 (1991).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the subunit of Gs in human thyroid neoplasms. J. Clin. Endocrinol. Metab.76(6), 1446–1451 (1993).
   PubMed Web of Science ®Google Scholar
• Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gs in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J. Clin. Endocrinol. Metab.81(11), 3898–3901 (1996).
   PubMed Web of Science ®Google Scholar
• Ledent C, Dumont JE, Vassart G, Parmentier M. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J.11(2), 537–542 (1992).
   PubMed Web of Science ®Google Scholar
• Michiels FM, Caillou B, Talbot M et al. Oncogenic potential of guanine nucleotide stimulatory factor α subunit in thyroid glands of transgenic mice. Proc. Natl Acad. Sci. USA91(22), 10488–10492 (1994).
   PubMed Web of Science ®Google Scholar
• Zeiger MA, Saji M, Gusev Y et al. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology138(8), 3133–3140 (1997).
   PubMed Web of Science ®Google Scholar
• Fagin JA. Branded from the start – distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endocrinol.16(5), 903–911 (2002).
   PubMedGoogle Scholar
• Kato Y. Ying, H. Willingham MC et al. A tumor suppressor role for thyroid hormone β receptor in a mouse model of thyroid carcinogenesis. Endocrinology145(10), 4430–4438 (2004).
   PubMed Web of Science ®Google Scholar